We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......

Basic View | Expanded View
 Showing 1-20 of 79 Articles
Ofer Merin, MD; Avraham Yitzhak, MD; Tarif Bader, MD

This Viewpoint identifies strategies for the appropriate and efficient emergency medical team assistance to other countries following natural disasters.

Mary K. Brennan-Taylor, BA

At 88 years of age, my mother, Alice, felt nagging pain in her neck and shoulders. She had been invited to several parties on July 4th and did not want the pain to crimp her enjoyment of the holiday. Her primary care physician’s office was closed for the ...

Original Investigation 
Steven B. Zeliadt, PhD, MPH; Jaimee L. Heffner, PhD; George Sayre, PsyD; Deborah E. Klein, MD; Carol Simons, BA; Jennifer Williams, BA; Lynn F. Reinke, PhD, APRN; David H. Au, MD, MS

Importance  Broad adoption of lung cancer screening may inadvertently lead to negative population health outcomes if it is perceived as a substitute for smoking cessation.

Objective  To understand views on smoking cessation from current smokers in the context of being offered lung cancer screening as a ...

Invited Commentary: The Psychological Effects of Lung Cancer Screening on Heavy Smokers ; Russell P. Harris, MD, MPH
Invited Commentary 
Russell P. Harris, MD, MPH

This Invited Commentary discusses the potential harms to heavy smokers undergoing screening for lung cancer.

The Belmont Report1 formally established ethical principles and guidelines in 1979 for the protection of human research subjects in the United States. Summarizing discussions among the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research from an initial 4-day meeting at the Smithsonian ...

Our awareness of the potential adverse effects (AEs) of newly approved drugs and devices is limited. Premarket trials are often small and of limited duration, and the patients in clinical trials are healthier than unselected patients in routine clinical practice. Thus, the public and physicians rely on the ...

Research Letter 
Tanya Bhattacharya, BS; Debra G. Tice, MS; Pranathi Lingam, MD; Aleksandra Florek, MD; Eileen M. Yates, MS; Sigmund Weitzman, MD; Steven M. Belknap, MD

This database review assesses the disclosure to study participants of boxed warning risks on consent forms.

Editor's Note: Informed Consent and Research on Higher-Risk Medications; Joseph S. Ross, MD, MHS
Research Letter 
Paul Ma, PhD; Iván Marinovic, PhD; Pinar Karaca-Mandic, PhD

This study investigates patient and event characteristics associated with manufacturers’ delayed submission of expedited adverse event reports to the US Food and Drug Administration.

Editor's Note: Improving Manufacturer Reporting of Adverse Events to the FDA ; Rita F. Redberg, MD, MSc
Teachable Moment 
Christopher Worsham, MD; Jason Ackrivo, MD; Anthony C. Breu, MD

The earliest safe withdrawal of sedation and mechanical ventilation leads to reduced risk of complications, reduced ICU and hospital stay, as well as reduced costs and utilization of resources.

Original Investigation 
Chang-Fu Kuo, MD, PhD; Matthew J. Grainge, PhD; Ana M. Valdes, PhD; Lai-Chu See, PhD; Shue-Fen Luo, MD; Kuang-Hui Yu, MD; Weiya Zhang, PhD; Michael Doherty, MD
Includes: Supplemental Content

Importance  Relatives of patients with systemic lupus erythematosus (SLE) appear to be at higher risk of SLE and other autoimmune diseases, but estimates of individual familial risks are largely unavailable or unreliable. Furthermore, relative contributions of genetic, shared, and unshared environmental factors to SLE susceptibility remain unclear....

Invited Commentary: Nationwide Population Science: Lessons From Taiwan; Ann W. Hsing, PhD; John P. A. Ioannidis, MD, DSc
Original Investigation 
Chien-Yi Yang, BS; Chi-Hua Chen, MS; Shin-Tarng Deng, MS; Chi-Shan Huang, MS; Yu-Jr Lin, BA; Yi-Ju Chen, MD, PhD; Chun-Ying Wu, MD, PhD; Shuen-Iu Hung, PhD; Wen-Hung Chung, MD, PhD

Importance  Allopurinol, a first-line drug used for treating gout, is increasingly prescribed worldwide to patients with asymptomatic hyperuricemia and comorbid renal or cardiovascular diseases. Nevertheless, allopurinol use has been associated with fatal hypersensitivity reactions, including drug rash with eosinophilia and systemic symptoms, Stevens-Johnson syndrome, and toxic epidermal ...

Editor's Note: Reducing Life-Threatening Allopurinol Hypersensitivity; Rachel J. Stern, MD
Invited Commentary 
Ann W. Hsing, PhD; John P. A. Ioannidis, MD, DSc

Large population-based studies can inform us on the prevalence, incidence, natural history, treatment, correlates, and associations of disease, as well as the pattern of health care utilization. A special type of large population study encompasses the population of an entire nation. Advantages include enormous sample size and lack ...

Editor's Note 
Joseph S. Ross, MD, MHS

Promoting evidence-based high-value health care remains one of the foremost challenges in medicine today. Increasing scrutiny of the real-world effectiveness, safety, and costs of medical care, including therapeutics, diagnostic tests, procedures, operations, and even decisions regarding whether to admit a patient to the hospital or schedule an outpatient ...

Editor's Note 
Rachel J. Stern, MD

Allopurinol is the cornerstone of pharmacologic urate-lowering therapy for recurrent gouty arthritis. Although this drug is inexpensive and efficacious, it may cause rare, but life-threatening, cutaneous drug eruptions: the allopurinol hypersensitivity syndrome.1 Mortality rates for individuals experiencing allopurinol hypersensitivity can exceed 30% and long-term morbidity is common....

Research Letter 
Jennifer X. Cai, MD, MPH; Emily J. Campbell, MPH; James M. Richter, MD, MA

This study investigated the factors associated with discordance with the American College of Physician guidelines for esophagogastroduodenoscopy in adult outpatients.

Editor's Note: Promoting Evidence-Based High-Value Health Care; Joseph S. Ross, MD, MHS
Teachable Moment 
Hina N. Mehta, MD; Xue Chi; Fred R. Buckhold, MD

In this case, a patient was exposed to several potential harms to prevent consequences of a low-risk procedure.

Original Investigation 
Eric G. Campbell, PhD; Christine Vogeli, PhD; Sowmya R. Rao, PhD; Melissa Abraham, PhD; Roz Pierson, PhD; Sandra Applebaum, MA
Includes: Supplemental Content

Importance  For the past decade, more attention and concern has been directed toward financial relationships between the life science industry and physicians. Relationships between industry and institutional review board (IRB) members represent an important subclass that has the potential to broadly influence decisions regarding medical research.


Invited Commentary: Advancing Science in the Service of Humanity; Laura Weiss Roberts, MD, MA
Original Investigation 
Walter Ageno, MD; Nicoletta Riva, MD; Sam Schulman, MD; Jan Beyer-Westendorf, MD; Soo Mee Bang, MD; Marco Senzolo, MD; Elvira Grandone, MD; Samantha Pasca, MD; Matteo Nicola Dario Di Minno, MD; Rita Duce, MD; Alessandra Malato, MD; Rita Santoro, MD; Daniela Poli, MD; Peter Verhamme, MD; Ida Martinelli, MD; Pieter Kamphuisen, MD; Doyeun Oh, MD; Elbio D’Amico, MD; Cecilia Becattini, MD; Valerio De Stefano, MD; Gianpaolo Vidili, MD; Antonella Vaccarino, MD; Barbara Nardo, MD; Marcello Di Nisio, MD; Francesco Dentali, MD
Includes: Supplemental Content

Importance  Little information is available on the long-term clinical outcome of patients with splanchnic vein thrombosis (SVT).

Objective  To assess the incidence rates of bleeding, thrombotic events, and mortality in a large international cohort of patients with SVT.

Design, Setting, and Participants  A prospective cohort ...

Invited Commentary 
Laura Weiss Roberts, MD, MA

Is human experimentation ever ethically permissible? Are human studies always and inevitably exploitative? Since the release of the Belmont Report1 in the United States in 1979, the response to these difficult ethical questions has been that people may participate in scientific studies when the following 2 conditions ...

Invited Commentary 
Jack Ansell, MD

The commentary discusses the implications of the study on anticoagulant therapy for splanchnic vein thrombosis from the International Society on Thrombosis and Hemostasis registry.

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts